Bladder Cancer Treatment Enters 'Post-Checkpoint' EraBig pharmas still think they can get there with their immuno-therapy strategy ...
Early trials show responses with antibody-drug conjugates
"
Although these agents are extremely effective, they do not benefit the majority of patients," said discussant Matthew Milowsky, MD, of the University of North Carolina at Chapel Hill. "
In having the success with immune checkpoint inhibitors, we've created a new clinical disease state, namely the post–immune checkpoint inhibitor space," he said.